Santen Pharmaceutical Co Ltd (Santen) manufactures and commercializes medicine for eye care, including eye drops and ointments.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Santen's R&D activities are focused on developing medicines for the treatment of unmet medical needs in ophthalmology worldwide. The company’s pipeline products are aimed at the treatment of various ophthalmic indications such as dry eye, posterior uveitis, ocular hypertension, glaucoma, and myopia. Santen is exploring new frontiers in Myopia, Presbyopia, Ptosis, and Retinitis Pigmentosa. The company emphasizes patient-centric innovation by studying patient journeys and collaborating with key opinion leaders to develop therapeutic options. Santen is also working on improving existing products, such as reducing the concentration of benzalkonium chloride in ophthalmic solutions and developing new formulations to enhance treatment adherence. The pipeline products of the company include, STN1011101/ DE-111A- Glaucoma, Ocular Hypertension; STN1012600 / DE-126- Glaucoma, Ocular Hypertension (Sepetaprost); STN1012700 / DE-127- Myopia; STN1013001/ DE-130A- Glaucoma, Ocular Hypertension; STN1013900/ AR-13324- Glaucoma, Ocular Hypertension; STN1012701 SYD-101- Myopia; STN1013400- Myopia; STN1013800 RVL-1201- Ptosis; STN1010904- Fuchs Endothelial Corneal Dystrophy; STN1010905- Meibomian Gland Dysfunction. The company carries out basic research, drug formulation research and non-clinical studies at its Nara R&D Center in Japan. It also operates R&D facilities in Japan, Finland, the US, China, where it conducts drug discovery and clinical development. The company offers grants to clinicians, scientists and academic institutions who are pursuing research on company’s medical devices, and compounds. Santen provides research support in therapeutic areas including glaucoma, retinal disorders, dry eye, corneal disorders, and other anterior segment conditions. It also works in partnership with other pharmaceutical companies, research institutes and universities to discover and launch new therapies for the treatment of various ophthalmological indications. In FY2025, the company spent JPY24,103 million on its R&D, which as a percentage of revenue stood at 8.03%.